| Ytd | 15.90% | |
| 1y | -0.74% |
| Open | 7.66 | Prev Close | 7.69 | Low | 7.30 | High | 8.02 | Mkt Cap | 22.57M |
| Vol | 29.71K | Avg Vol | 9.16K | EPS | -18.33 | P/E | N/A | Forward P/E | -1.59 |
| Beta | 2.08 | Short Ratio | 3.79 | Inst. Own | 21.64% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 7.09 | 200-d Avg | 7.28 | 1yr Est | 9.50 |
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan
Veteran physician , medical affairs and clinical research leader brings 30 years of rehabilitation m
Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript
Lifeward (LFWD) came out with a quarterly loss of $6.7 per share versus the Zacks Consensus Estimate
Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisi
HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFW
Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past si
Lifeward Ltd. (NASDAQ: LFWD - Get Free Report) shares were up 2.5% on Thursday. The stock traded as
Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innova
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Lifeward (NASDAQ:LFWD) with a Bu
Lifeward Ltd. (LFWD) Q4 2025 Earnings Call Transcript
Lifeward (NASDAQ:LFWD) reported quarterly losses of $(2.85) per share which missed the analyst conse
Advancing t ransformation into a d iversified b iomedical i nnovation c ompany with a c lear p ath t
Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innov
Position s Lifeward as a diversified biomedical innovation company with clear path to profitability
Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innov
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasd
Clinic d ays offered at Shirley Ryan AbilityLab, the #1 ranked rehabilitation hospital for 35 conse
IP and technology acquisition is expected to be highly accretive and to advance Lifeward's position
Reverse split initiated as Lifeward enters strategic partnership agreement and repositions as MedTec
Aetna joins Humana and United Healthcare in providing Medicare Advantage coverage for beneficiaries
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and
Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotec
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Pos
Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innov
Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal E
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Lifeward (NASDAQ:LFWD) with a Bu
Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in inno
Lifeward (NASDAQ:LFWD) affirms FY2025 sales outlook from $24.000 million-$26.000 million to $24.000
Lifeward (NASDAQ:LFWD) reported quarterly losses of $(0.19) per share which beat the analyst consens
Medicare Advantage claim processed in less than thirty daysAdditional progress with traditional Medi
Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innov
https://sam.gov/opp/09d936af89b2496392773ea6302bda5c/view
Lifeward (NASDAQ:LFWD) lowers FY2025 sales outlook from $28.000 million-$30.000 million to $24.000 m
Rewalk Robotics (NASDAQ:LFWD) reported quarterly losses of $(0.31) per share which missed the analys